Valneva SE - Company Profile
Powered by 
All the sales intelligence you need on Valneva SE in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Valneva SE fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Valneva SE.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Valneva SE (Valneva) is a speciality vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. The company produces vaccines for chikungunya, Lyme disease, and Japanese encephalitis. Its major products include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine, to treat active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholerae; and IXCHIQ, a single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older. The company's products are used by travelers, military personnel, and individuals through collaboration with pharmaceutical companies and a distribution network. It operates manufacturing sites in Scotland, Sweden, and Austria. The company also distributes certain third-party vaccines in countries where it operates its own marketing and sales infrastructure. Valneva is headquartered in Saint-Herblain, Lorraine, France.
Headquarters
France
Address
6, Rue Alain Bombard, Lyon, Lorraine, 69002
Website
www.valneva.com
Telephone
33 228 073710
No of Employees
674
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VLA (EPA)
Revenue (2024)
$197.1M
3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-840.6%
(2024 vs 2023)
Market Cap*
$485.3M
Net Profit Margin (2024)
XYZ
-813.4%
(2024 vs 2023)
* As of and is in US$
Valneva SE premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Japanese Encephalitis Vaccine | Distribution Services for Third-Party Products | IXIARO |
| Cholera Vaccine | DUKORAL | |
| IXCHIQ: Chikungunya Vaccine | JESPECT | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In December, the company and Serum Institute of India terminated their chikungunya vaccine licensing agreement to end the single-injection collaboration. |
| 2025 | Contracts/Agreements | In June, the company entered into an agreement with CSL Seqirus for marketing and distribution of its three vaccines in Germany. |
| 2025 | Regulatory Approval | In April, the company secured marketing authorisation from the Brazilian Health Regulatory Agency for its single-dose chikungunya vaccine, Ixchiq for individuals aged 18 years and above. |
Competitor Comparison
| Key Parameters | Valneva SE | Sanofi | Takeda Pharmaceutical Co Ltd | Baxter International Inc | Tarsus Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | France | France | Japan | United States of America | United States of America |
| City | Lyon | Paris | Chuo-Ku | Deerfield | Irvine |
| State/Province | Lorraine | Ile-de-France | Tokyo | Illinois | California |
| No. of Employees | 674 | 76,493 | 47,455 | 37,500 | 370 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James Sulat | Director; Vice Chairman | Executive Board | 2005 | 75 |
| Thomas Lingelbach | President; Director; Chief Executive Officer | Executive Board | 2013 | 62 |
| Peter Buhler | Chief Financial Officer | Senior Management | 2022 | 56 |
| Vincent Dequenne | Chief Operating Officer | Senior Management | 2022 | 58 |
| Petra Pesendorfer | Chief People Officer | Senior Management | 2024 | 40 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer